Download Unicorn Signals App

By EquityPandit

Latest News

Zydus Cadila has received USFDA’s final approval to sell generic diabetes drug

The US health regulator has provided its final approval to the drug firm Zydus Cadila for marketing anti-diabetic Glyburide tablets in the American market.

Zydus Cadila has said in a statement that the group has got final approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 1.25, 2.5 and 5 mg.

The production of Glyburide will be done at the group’s formulations manufacturing facility at Baddi (Himachal Pradesh).

Read EquityPandit’s Nifty Pharma Outlook for this week 

Get Daily Prediction & Stocks Tips On Your Mobile


Latest
IPO
Weekly
Outlook

Stock
Market
Prediction